Entolimod is currently in clinical development
as a potential treatment for acute radiation syndrome with
additional preclinical programs advancing in neutropenia and anemia
in cancer patients
WEXFORD, Pa. , April 13,
2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC
PINK: COEP), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, today announced that the Company has
entered into a strategic agreement with Statera Biopharma, Inc.
(Nasdaq: STAB) that gives Coeptis the right to acquire Statera's
toll-like receptor 5 (TLR5) agonist platform, including entolimod,
a clinical-stage product currently being developed as a treatment
for acute radiation syndrome. The consummation of the transaction
is contingent upon negotiation of a definitive agreement and
satisfaction of a number of closing conditions, including a
financing contingency. Coeptis and Statera have agreed to an
exclusivity period through the date that is 30 days following the
date on which the first draft of the definitive agreement is
available to review by both parties.
Under the terms of the definitive agreement, Coeptis will agree
to pay Statera Biopharma six million
USD ($6,000,000) and
revenue-based milestone payments to be defined in the definitive
agreement in exchange for a defined set of purchased assets that
include Statera's rights to any product containing entolimod as an
active ingredient and all other related TLR5 agonists, related
intellectual property, contract rights, inventory and data related
to such products.
TLR5 is an innate immunity receptor, which when activated,
triggers nuclear factor kappa B (NF-kB) signaling, mobilizing an
innate immune response that drives expression of numerous genes,
including inhibitors of apoptosis, scavengers of reactive oxygen
species, and a spectrum of protective or regenerative
cytokines. Entolimod is Statera's most advanced TLR5 agonist
technology and is currently in development to treat acute radiation
syndrome. Entolimod has also demonstrated preclinical potential in
hematology, specifically the treatment of neutropenia and anemia in
cancer patients.
"The proposed addition of Statera's TLR5 agonist platform, led
by entolimod, a late-stage clinical candidate, offers the potential
to significantly enhance our development pipeline and target
multiple disease indications that remain underserved by current
therapeutic options," said Dave
Mehalick, President and Chief Executive Officer of Coeptis
Therapeutics. "We are particularly intrigued by the opportunity to
advance the development of entolimod for acute radiation syndrome
given the current geopolitical climate, which unfortunately
elevates the need for medications to address extreme radiation
exposure. Moreover, the opportunity to pursue programs in
neutropenia and anemia in cancer patients complements Coeptis'
mission to improve outcomes for patients with cancer."
About Coeptis Therapeutics
Coeptis Therapeutics, Inc.,
along with its wholly owned subsidiary Coeptis Pharmaceuticals,
Inc. (together "Coeptis"), is a biopharmaceutical company
developing innovative cell therapy platforms for cancer that have
the potential to disrupt conventional treatment paradigms and
improve patient outcomes. Coeptis' product portfolio and
rights is highlighted by a cell therapy technology (CD38-GEAR-NK)
and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related
cancers, which the company is developing with VyGen Bio and leading
medical researchers at the Karolinska
Institutet. Coeptis' business model is designed around
maximizing the value of its current product portfolio and rights
through in-license agreements, out-license agreements and
co-development relationships, as well as entering into strategic
partnerships to expand its product rights and offerings,
specifically those targeting cancer. Coeptis was founded in 2017
and is headquartered in Wexford,
PA. For more information on Coeptis visit
https://coeptistx.com/.
Forward Looking Statement
This press release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When we use words such as "may,"
"will," "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Forward-looking statements are not guarantee of
future performance and involve risks and uncertainties that may
cause the actual results to differ materially from our expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited, to
those risks contained in reports filed by us with the Securities
and Exchange Commission. For these reasons, among others,
investors are cautioned not to place undue reliance upon any
forward-looking statements in this press release. Additional
factors are discussed in our filings with the U.S. Securities and
Exchange Commission, which are available for review
at www.sec.gov. We undertake no obligation to publicly revise
these forward–looking statements to reflect events or circumstances
that arise after the date hereof unless required by applicable
laws, regulations or rules.
CONTACT
Tiberend Strategic Advisors, Inc.
Investors
Lisa Sher
lsher@tiberend.com
Media
David Schemelia
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-announces-intent-to-acquire-tlr5-agonist-platform-including-clinical-stage-asset-entolimod-from-statera-biopharma-301524610.html
SOURCE Coeptis Therapeutics